BioRestorative Therapies, Inc. · NASDAQ:BRTX
BioRestorative Therapies — Innovations Conference 2015
28 slides from BioRestorative Therapies's conference presentation, Feb 9, 2015
Slide 1: BioRestorative Therapies: A Stem Cell Biotechnology Company
PAGE 1 BioRestorative Therapies A Stem Cell Biotechnology Company Innovations Conference February 9, 2015 www.biorestorative.com
Slide 2: Forward Looking Statements
Forward Looking Statements PAGE 2 This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including statements concerning the ability of BioRestorative Therapies, Inc. (the Company ) to develop its adult stem cell business, the future of regenerativ
Slide 3: BioRestorative Therapies (BRT)
BioRestorative Therapies (BRT) PAGE 3 Research and Development focus cell based therapies brtxDISC™ Mesenchymal stem cells for the treatment of chronic Lumbar Disc Disease (cLDD) Lead therapeutic product – successful pre-IND meeting ThermoStem® Brown adipose tissue preclinical program for the treatm
Slide 4: BRT's Lead Therapeutic Product: brtxDISC
BRT’s Lead Therapeutic Product: brtxDISC™ PAGE 4 Addressing the pathophysiology and symptoms of intervertebral disc disease www.biorestorative.com 4
Slide 5: brtxDISC Treatment for Lumbar Disc Disease
PAGE 5 brtxDISC™ Treatment for Lumbar Disc Disease brtxDISC™ is BioRestorative Therapies’ lead product candidate brtxDISC™ is an autologous hypoxic cultured Mesenchymal Stem Cell (MSC) product derived from adult human bone marrow formulated with a proprietary carrier 13/132,840 Methods and Compositi
Slide 6: The Market Opportunity: Lower Back Pain (LBP)
The Market Opportunity: Lower Back Pain (LBP) PAGE 6 LBP is the most common, disabling and costly musculoskeletal problem Global population prevalence of LBP 84% of populace with an occurrence during lifetime 23% with pain recurrence within 6 months 11% with chronic LBP Out of 291 medical conditions
Slide 7: The Problem: No Good Treatments for Lower Back Pain
The Problem: No Good Treatments for Lower Back Pain PAGE 7 Today’s treatments do not address the pathophysiology of the disease Non-Surgical treatments Physical therapy and weight loss Non-steroidal anti-inflammatory drugs Spinal manipulation (chiropractic care) Epidural steroid injections Surgical
Slide 8: The Solution: brtxDISC to treat Lumbar Disc Disease
PAGE 8 The Solution: brtxDISC™ to treat Lumbar Disc Disease The clinical benefit of mesenchymal stem cells (MSCs) is due to a number of mechanisms that act upon the site of pathology in the disc Replacement: MSCs differentiation into chondrocytes Repair/Regeneration: Activation of certain beneficial
Slide 9: brtxDISC Treatment Process
brtxDISC™ Treatment Process PAGE 9 brtxDISC™ production begins with the physician collecting (1) bone marrow and (2) blood plasma from the patient Bone marrow harvested from the patient’s iliac crest under a local anesthesia Peripheral blood collected from the patient Physician sends patient bone ma
Slide 10: Clinical Results from a Physician Sponsored Study
Clinical Results from a Physician Sponsored Study PAGE 10 Patients received injection of autologous Mesenchymal Stem Cells to the intervertebral disc Autologous mesenchymal stems cells are safe No adverse events observed Maximum dose of 40 million stem cells well tolerated Mesenchymal stems cells ar
Slide 11: Impact of Stem Cells on Disc Morphology
Impact of Stem Cells on Disc Morphology PAGE 11 MRIs of patient treated with BioRestorative Stem Cell Technology Before stem cell After stem cell treatment treatment Stem cells may have a significant impact on the morphology of the disc and bring relief of symptoms www.biorestorative.com
Slide 12: Clinical Development Plans
Clinical Development Plans PAGE 12 brtxDISC™ is an autologous MSC product injected into the intervertebral disc. MSCs will be formulated with a proprietary carrier. Therapeutic application of brtxDISC™ in treatment of cLDD delivered by a standard 20G 3.5 inch introducer needle and a 25G 6 inch needl
Slide 13: brtxDISC Clinical Trial Principal Investigators
brtxDISC™ Clinical Trial Principal Investigators PAGE 13 Gregory E. Lutz, M.D.; BRT Chief Medical Advisor for Spine Medicine Physiatrist-in-Chief Emeritus for Hospital for Special Surgery (HSS) and is a member of the Board of Trustees Regenerative Medicine clinical trial experience Associate Profess
Slide 14: Target Physicians Likely To Treat Discs with Stem Cells
Target Physicians Likely To Treat Discs with Stem Cells PAGE 14 Large pool of physicians in the United States that will use brtxDISC™ Physicians currently trained and skilled in performing spinal injections are the target physicians for injections of brtxDISC™ Interventional physiatrists (physical m
Slide 15: brtxDISC Revenue Assumptions
brtxDISC™ Revenue Assumptions PAGE 15 brtxDISC™ effective in a wide spectrum of lumbar disc disease (from IDD to protrusions to moderate/severe disc degeneration) Non-steep learning curve for physicians Up to 10% market penetration in the first year Maximum market penetration of 80% by year 5 $15,00
Slide 16: Pipeline Overview and Anticipated Progress in 2015
PAGE 16 Pipeline Overview and Anticipated Progress in 2015 Program Preclinical Phase 1 Phase 2 Phase 3 Autologous Begin Phase 1/2a 2015 brtxDISC™ Allogeneic brtxDISC™ Proprietary Development Project www.biorestorative.com
Slide 17: Market Adoption Strategy
Market Adoption Strategy PAGE 17 Phase 3 study showing a clinically meaningful effect of MSCs treating disc protrusions will help drive market adoption Long term follow-up data confirming the safety and efficacy of the therapy Company plans to conduct other supportive studies Promotional activities
Slide 18: Strategic Partnerships for Distribution
PAGE 18 Strategic Partnerships for Distribution Strategic partner will be sought for the marketing and distribution of brtxDISC™ Partner characteristics include Sales force with presence in the spine/orthopedic care setting Expertise and vision for the growth of the regenerative medicine market BioR
Slide 19: ThermoStem Program (Brown Fat Stem Cells)
PAGE 19 ThermoStem® Program (Brown Fat Stem Cells) Potential Treatments for Metabolic Diseases Magnification of brown adipose derived stem cells cultured and differentiated into brown adipocytes on porous extracellular matrix scaffolds www.biorestorative.com
Slide 20: Metabolic Platform Program
PAGE 20 Metabolic Platform Program Obesity Metabolic Syndrome Hypertension Myopathies Insulin Diabetes Resistance Atherosclerosis Dyslipidaemia www.biorestorative.com 20
Slide 21: ThermoStem Brown Fat Program
ThermoStem® Brown Fat Program PAGE 21 One of the most powerful organs in the body….Since it consumes both glucose and fatty acids, it is possible we could utilize brown fat to treat obesity and metabolic dysfunction seen in diabetes and hyperlipidemia. Aaron M. Cypress, M.D., Ph.D., Joslin Diabetes
Slide 22: BRT February 2014 Publication in STEM CELLS
Volume 32, Number 2, February 2014 PAGE 22 The International Journal of Cell Differentiation and Proliferation B BRT February 2014 Publication in STEM CELLS Journal I NSIDE THIS I SSUE See Complete Table of Contents Inside 327 An Osteopontin-Integrin Interaction Plays a Critical Role in Directing A
Slide 23: BioRestorative Therapies/Pfizer Collaboration
PAGE 23 BioRestorative Therapies/Pfizer Collaboration Jointly conducting a study entitled “Development and Validation of a Human Brown Adipose Cell Model” BRT has a collection of human brown adipose tissue samples, pre-adipocyte cell lines and immortalized cell lines Characterization of identity and
Slide 24: Preclinical Study Results on Glucose and Body Weight
Preclinical Study Results on Glucose and Body Weight PAGE 24 Basal Blood Glucose Levels Body Weight 600 40 35 500 A B 30 400 25 Glucose (mg/dl) Body weight (g) 300 20 15 200 10 100 5 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 Control 1 2 3 4 5 6 7 8 9 10 11 12 13 Control Weeks after transplantation Weeks aft
Slide 25: Preclinical Study Results on Triglyceride and Cholesterol Levels
Preclinical Study Results on Triglyceride and Cholesterol Levels PAGE 25 Baseline 1Mth 2Mth 3Mth 4Mth Trig – ctrl mg/dL 115±16 147±13 159±21 165±14 188±16 Trig – tx mg/dL 120±14 142±15 131±19 113±11 114±10 Chol – ctrl mg/dL 136±16 151±15 188±26 224±34 251±22 Chol – tx mg/dL 125±12 130±14 136±24 126±
Slide 26: BioRestorative Therapies Pipeline Summary
BioRestorative Therapies Pipeline Summary PAGE 26 Intervertebral Disc Therapeutic Program Candidate Preclinical Product Product ID Design Studies Characterization Human Clinical Studies brtxDISC™ Autologous brtxDISC™ Allogeneic Brown Fat Therapeutic Program Candidate Preclinical Product Product ID D
Slide 27: In Summary
PAGE 27 In Summary brtxDISC™ Successful pre-IND meeting with FDA Expect to commence clinical trial by year end ThermoStem® Maintenance and regulation of metabolism Metabolic Platform (Brown Fat) Program addresses large markets Pfizer collaboration Deep expertise in stem cell biology and public manag
Slide 28: Thank You
PAGE 28 Thank You OTCBB: BRTX www.biorestorative.com 28
BioRestorative Therapies — Innovations Conference 2015 on 6ix